Alterations in the homeostasis of the GR and GPX group of antioxidant enzymes, have been implicated in the enterology and or progression of many human diseases e.g
[1,2] More specifically, it's a GLP-1R agonist it activates the receptor, rather than inhibiting it
Another critical limitation lies in the complexity of dosing and timing
In this installment, were highlighting safety updates concerning these drugs: Byetta, Bydureon BCISE, Mounjaro, Saxenda, Soliqua 100/33, Trulicity, Victoza, and Xultophy 100/3.6
We focused on: Topical nutrients (Vitamin D, B12, and B6) to calm inflammation and strengthen the skin barrier Dietary adjustments to remove inflammatory triggers Gut and microbiome support to address underlying drivers This was not about finding a better cream.It was about supporting the bodys ability to heal
No change in lesion size or extent has been noted in the last 12 months